RxDoctor Payments Data

Soham Sheth

Neurology · Chesapeake, VANPI 1386835841

Payments from drug & device makers

$6,792in general payments, 2019–2025

Across 383 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$974
  • Pfizer$310
  • Jazz Pharmaceuticals Inc.$246
  • Lundbeck LLC$229
  • AstraZeneca$223
  • plus $4K from 52 others

What the payments were for

  • Consulting fees$3115%
  • Speaking & faculty fees$230%
  • Food & beverage$6,37194%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,792 in reported general payments places this provider in the 65th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$359,305
Medicare patients
1,052
Services billed
11,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5014$496,233
Gamunex-CImmune Globul G/Gly/Iga Avg 4625$289,427
AustedoDeutetrabenazine15$188,394
VumerityDiroximel Fumarate11$110,446
QuliptaAtogepant45$71,722
Aimovig AutoinjectorErenumab-Aooe56$60,335
Nurtec OdtRimegepant Sulfate37$51,114
Emgality PenGalcanezumab-Gnlm26$32,957
UbrelvyUbrogepant21$25,262
Ajovy AutoinjectorFremanezumab-Vfrm18$17,541
BelsomraSuvorexant30$13,610
FingolimodFingolimod Hcl12$7,028
Memantine Hcl204$6,379
Modafinil58$5,338
Pregabalin96$4,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$40$496,23314 claims
Grifols USA, LLCGamunex-C$50$289,42725 claims
Teva Pharmaceuticals USA, Inc.Austedo$201$188,39415 claims
BiogenVumerity$974$110,44611 claims
AbbVieQulipta, Ubrelvy$1,092$96,98366 claims
PfizerNurtec Odt$310$51,11437 claims
MerckBelsomra$106$13,61030 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$84$1,39515 claims
Upsher-smith Laboratories LLCTopiramate$13$1,17167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 474 neurology providers in Virginia.

Other neurology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →